ArticleJournal of medical case reports2026
Possible bronchospasm relief following flumazenil administration in a remimazolam-induced Grade III hypersensitivity reaction: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRemimazolam is an ultrashort-acting benzodiazepine for procedural sedation, with rare reports of anaphylaxis. Its clinical phenotypes and management strategies for refractory cases with suboptimal adrenaline response remain poorly defined. As remimazolam use increases globally, exploring effective interventions for its induced hypersensitivity reactions is clinically important. This report presents a rare remimazolam-induced Grade III hypersensitivity reaction dominated by bronchospasm, with flumazenil administration temporally associated with improvement of adrenaline-refractory symptoms, adding a hypothesis-generating observation to the existing literature. CASE PRESENTATION: A 49-year-old Han female developed a Grade III hypersensitivity reaction after remimazolam administration for gastroscopy sedation, with no prior allergic history or underlying diseases. The main symptoms included severe persistent bronchospasm (initial and dominant manifestation), facial flushing, nausea, vomiting, abdominal pain, and hemodynamic instability (peripheral oxygen saturation 83%, blood pressure 75/53 mmHg, tachycardia). Discontinuation of remimazolam and stepwise adrenaline bolus administration failed to relieve bronchospasm effectively. Intravenous flumazenil administration, combined with an additional adrenaline dose, was temporally associated with the gradual resolution of all allergic symptoms and hemodynamic stabilization. The adrenaline dosing followed international perioperative anaphylaxis management consensus, with stepwise escalation based on the patient's clinical response and American Society of Anesthesiologists physical status I.
conclusionsRemimazolam-induced hypersensitivity reactions can present as Grade III cases dominated by bronchospasm, requiring prompt clinical recognition and targeted intervention. The temporal association between flumazenil administration and relief of adrenaline-refractory bronchospasm warrants further investigation, but this observation is hypothesis-generating only; the independent therapeutic effect and mechanism of flumazenil remain unproven and require confirmation by more studies. For suspected remimazolam-induced anaphylaxis, serum tryptase measurement and convalescent allergen skin testing are recommended to confirm diagnosis and guide subsequent anesthetic selection. This single case report has inherent limitations, and clinical improvement may result from the combined effect of multiple interventions, so no definitive conclusion can be drawn regarding flumazenil's role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.